Edition:
United States

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Global Market

1.53USD
10:46am EST
Change (% chg)

$-0.02 (-1.29%)
Prev Close
$1.55
Open
$1.56
Day's High
$1.56
Day's Low
$1.53
Volume
5,699
Avg. Vol
18,108
52-wk High
$5.70
52-wk Low
$1.48

CYTX.OQ

Chart for CYTX.OQ

About

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused... (more)
No analyst recommendations are available for CYTX.OQ.

Overall

Beta: 2.70
Market Cap(Mil.): €29.65
Shares Outstanding(Mil.): 20.50
Dividend: --
Yield (%): --

Financials

  CYTX.OQ Industry Sector
P/E (TTM): -- 31.03 30.77
EPS (TTM): -8.22 -- --
ROI: -78.90 13.42 15.23
ROE: -286.17 17.11 16.56

BRIEF-Cytori announces 2-year follow-up published on EU scleroderma trial

* Cytori announces two year follow-up published on EU scleroderma trial Source text for Eikon: Further company coverage:

Nov 29 2016

BRIEF-Cytori granted FDA orphan drug designation for ECCS-50 in scleroderma

* Cytori granted FDA orphan drug designation for ECCS-50 in scleroderma Source text for Eikon: Further company coverage:

Nov 14 2016

BRIEF-Cytori Therapeutics Q3 loss per share $0.26

* Sees FY 2016 combined product and contract revenues anticipated to be within a range of $11 million to $13 million

Nov 09 2016

BRIEF-Cytori presents scleroderma clinical trial data at the 2016 American College Of Rheumatology annual meeting

* Cytori presents scleroderma clinical trial data at the 2016 American College of rheumatology annual meeting Source text for Eikon: Further company coverage:

Oct 26 2016

BRIEF-BARDA increases contract option with Cytori to advance Countermeasure Clinical Trial

* BARDA increases contract option with Cytori to advance countermeasure clinical trial

Sep 19 2016

BRIEF-Cytori Therapeutics Q2 loss per share $0.43

* Cytori reports second quarter 2016 business and financial results

Aug 04 2016

BRIEF-Cytori announces Maxillofacial bone regeneration trial reports

* Cytori Cell Therapy(tm) phase I trial reports Maxillofacial bone regeneration

Jul 19 2016

BRIEF-Cytori cell therapy receives limited approval in Japan

* Cytori cell therapy receives limited approval for osteoarthritis in japan

Jun 27 2016

Earnings vs. Estimates